
Nonstick pans face potential ban in New York amid health concerns
Some lawmakers in New York state are looking to ban nonstick pans in the Empire State.
Senate Bill S1767 would prohibit the manufacture, sale and use of cookware containing polytetrafluorethylene, which is commonly known as Teflon.
Teflon is also a member of PFAS.
These are known as "forever chemicals" because they take hundreds – or even thousands – of years to break down in the environment.
The chemical coating is commonly used on cookware to make it "nonstick."
The bill would ban Teflon cookware – including, but not limited to, pots, pans, skillets, grills, cooking utensils and cooking appliances.
The Make America Healthy Again Commission, chaired by U.S. Health and Human Services Secretary Robert F. Kennedy Jr., recently released a report assessing chronic diseases, particularly those suffered by children.
In the MAHA report, PFAS are tied to a harmful impact on children's health.
The report notes that "high levels of certain types of PFAS exposure [have] been associated with a variety of health effects, including immune suppression and changes in cholesterol in children."
"It is also possible for very small amounts of PFAS to enter foods through food packaging, processing and cookware," writes the U.S. Food & Drug Administration (FDA) on its site.
The FDA authorizes certain PFAS in cookware and food packaging.
"Because exposure to some types of PFAS has been linked to serious health effects, we are working to better understand PFAS in foods," says the FDA.
Steve Burns of the Cookware Sustainability Alliance, a nonprofit organization, told Fox News Digital his group has been meeting with many members of the New York state Senate and Assembly.
"We've presented that the nonstick coating material used on cookware is the same exact material used to coat a pacemaker and has been approved for use on both products by the U.S. FDA for over 60 years."
"The coating is a well-studied, completely stable and inert material that has been shown for decades to be safe, non-toxic and most importantly not water-soluble," he said.
"Several other states are following the science for nonstick cookware, and we continue to encourage New York State lawmakers to do the same."
In 2022, Australian researchers said that just one surface crack on a Teflon-coated pan could release around 9,100 plastic particles.
"Given the fact [that] PFAS [are] a big concern, these Teflon microparticles in our food might be a health concern, [which] needs investigating because we don't know much about these emerging contaminants," University of Newcastle researcher Dr. Cheng Fang – one of the study's authors – said in a release from Flinders University.
Fox News Digital reached out to the FDA for comment.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
FDA deploys generative AI tool Elsa to transform agency operations in historic move
In a major step toward modernizing its operations, the U.S. Food and Drug Administration (FDA) on Monday launched Elsa, a generative artificial intelligence (AI) tool, designed to help agency employees, including scientific reviewers and field investigators, work smarter and faster. Elsa is the regulator's first large-scale foray into generative AI and is being dubbed as a turning point for the agency. Built in a secure GovCloud environment, the tool gives staff the ability to quickly search and summarize internal documents without compromising sensitive research and data handled by FDA staff. More than a chatbot, the tool also allows FDA scientists and subject-matter experts to spend less time on tedious, repetitive tasks that often slow down the review the AI models do not train on information submitted by regulated industries, ensuring the confidentiality of proprietary research. 'Today marks the dawn of the AI era at the FDA with the release of Elsa, AI is no longer a distant promise but a dynamic force enhancing and optimizing the performance and potential of every employee,' the agency's Chief AI Officer, Jeremy Walsh, said. 'As we learn how employees are using the tool, our development team will be able to add capabilities and grow with the needs of employees and the agency.' The agency said it is already using the tool to speed up clinical protocol reviews, shorten the time needed for scientific evaluations, and identify high-priority inspection targets. FDA Commissioner Dr. Marty Makary said the launch came ahead of schedule and under budget due to strong collaboration among internal teams. 'Following a very successful pilot program with FDA's scientific reviewers, I set an aggressive timeline to scale AI agency-wide by June 30,' he said. 'Today's rollout of Elsa is ahead of schedule and under budget, thanks to the collaboration of our in-house experts across the centers.' Elsa is a large language model–powered AI tool designed to assist with reading, writing, and summarizing. It can summarize adverse events to support safety profile assessments, perform faster label comparisons, and generate code to help develop databases for nonclinical applications. It is seen as the first step in a broader strategy to embed AI into FDA workflows. 'Prioritizing efficiency and responsibility, the FDA launched Elsa ahead of schedule using an all-center approach. Leaders and technologists across the agency collaborated, demonstrating the FDA's ability to transform its operations through AI,' the agency within the U.S. Department of Health and Human Services said in a release. As employees use the tool, its developers plan to expand capabilities to meet emerging needs. This includes improving usability, data processing, generative-AI functions, and tailoring outputs to center-specific needs while maintaining strict information security and compliance with FDA policy. The agency-wide rollout was coordinated by Walsh, the agency's newly-appointed Chief AI Officer, and Sridhar Mantha. Walsh previously led enterprise-scale technology deployments across federal health and intelligence agencies, and Mantha recently led the Office of Business Informatics in CDER.
Yahoo
an hour ago
- Yahoo
New York, other states urge FDA to expand access to abortion pill
By Jonathan Stempel NEW YORK (Reuters) -The attorneys general of New York, California, Massachusetts and New Jersey asked the Food and Drug Administration to expand access to the abortion pill mifepristone, and remove outdated restrictions still in place 25 years after its approval. Thursday's petition came after Health and Human Services Secretary Robert F. Kennedy Jr told Congress last month he directed FDA Commissioner Marty Makary to review the pill, saying "alarming" new data suggested at minimum that the label should be changed. Mifepristone, together with the drug misoprostol, won FDA approval in 2000 for medication abortion in the first 10 weeks of pregnancy. Medication abortions account for more than half of U.S. abortions, though 28 states restrict access according to the nonprofit Guttmacher Institute, which focuses on reproductive health. The petition challenges FDA requirements that mifepristone prescribers be included in national and local abortion provider lists, patients attest in writing that they intend to end their pregnancies, and pharmacies perform a variety of recordkeeping. New York Attorney General Letitia James said the FDA's Risk Evaluation and Mitigation Strategy program imposes "medically unnecessary" rules that keep mifepristone out of reach of most primary care settings. She called the problem particularly acute in rural and other areas where getting abortions often requires lengthy travel. "There is simply no scientific or medical reason to subject it to such extraordinary restrictions," James said, referring to mifepristone. "The FDA must follow the science." Many states, primarily Republican-led or leaning, have restricted or substantially eliminated abortions in the three years since the U.S. Supreme Court overturned Roe v. Wade, the 1973 decision that legalized the procedure nationwide. The White House under Republican President Donald Trump has largely sided with abortion opponents, though Trump said during his 2024 campaign he did not plan to limit access to mifepristone. Last month, the administration asked a federal judge to dismiss, on procedural grounds, a lawsuit by three generally Republican states seeking to narrow such access. That lawsuit began during the administration of Democratic President Joe Biden, who generally supported abortion access. Seventeen other Democratic-led or -leaning states plus Washington, D.C. are separately suing the FDA in Spokane, Washington to loosen restrictions on mifepristone. They said doctors and pharmacies should be able to dispense the pill, as with most drugs, without special certifications. On May 30, the Trump administration urged a dismissal, saying the states didn't show the FDA's policy was flawed or the agency ignored important evidence.


News24
an hour ago
- News24
Kempton Park teen's amazing recovery after glass slices through his abdomen in freak accident
Supplied Be among those who shape the future with knowledge. Uncover exclusive stories that captivate your mind and heart with our FREE 14-day subscription trial. Dive into a world of inspiration, learning, and empowerment. You can only trial once.